Werewolf Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Werewolf Therapeutics Free Cash Flow (FCF) History (HOWL)
Werewolf Therapeutics reported −$60.3M in free cash flow for fiscal 2025, a decrease of $3.9M from the previous fiscal year.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$60.3M | −$3.9M | — | — |
| 2024 | 2024-12-31 | −$56.4M | −$23.1M | — | — |
| 2023 | 2023-12-31 | −$33.4M | $10.8M | — | — |
| 2022 | 2022-12-31 | −$44.2M | −$833,000 | — | — |
| 2021 | 2021-12-31 | −$43.4M | −$24.2M | — | — |
| 2020 | 2020-12-31 | −$19.2M | — | — | — |
Werewolf Therapeutics quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$11.0M | $3.4M | — | — |
| Q3 2025 | 2025-09-30 | −$15.2M | −$2.7M | — | — |
| Q2 2025 | 2025-06-30 | −$15.2M | −$970,000 | — | — |
| Q1 2025 | 2025-03-31 | −$18.9M | −$3.5M | — | — |
| Q4 2024 | 2024-12-31 | −$14.4M | −$9.6M | — | — |
| Q3 2024 | 2024-09-30 | −$12.5M | −$5.0M | — | — |
| Q2 2024 | 2024-06-30 | −$14.2M | −$3.1M | — | — |
| Q1 2024 | 2024-03-31 | −$15.4M | −$5.3M | — | — |
| Q4 2023 | 2023-12-31 | −$4.8M | $7.6M | — | — |
| Q3 2023 | 2023-09-30 | −$7.4M | $9.0M | — | — |
| Q2 2023 | 2023-06-30 | −$11.1M | −$9.7M | — | — |
| Q1 2023 | 2023-03-31 | −$10.1M | $3.9M | — | — |
| Q4 2022 | 2022-12-31 | −$12.4M | $557,000 | — | — |
| Q3 2022 | 2022-09-30 | −$16.4M | −$3.9M | — | — |
| Q2 2022 | 2022-06-30 | −$1.4M | $9.2M | — | — |
| Q1 2022 | 2022-03-31 | −$14.0M | −$6.6M | — | — |
| Q4 2021 | 2021-12-31 | −$12.9M | −$6.9M | — | — |
| Q3 2021 | 2021-09-30 | −$12.5M | −$7.5M | — | — |
| Q2 2021 | 2021-06-30 | −$10.6M | −$6.2M | — | — |
| Q1 2021 | 2021-03-31 | −$7.3M | −$3.5M | — | — |
| Q4 2020 | 2020-12-31 | −$6.0M | — | — | — |
| Q3 2020 | 2020-09-30 | −$5.0M | — | — | — |
| Q2 2020 | 2020-06-30 | −$4.3M | — | — | — |
| Q1 2020 | 2020-03-31 | −$3.8M | — | — | — |
Werewolf Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$19.2M to −$60.3M, a net decrease of $41.1M. Werewolf Therapeutics's latest reported quarter, Q4 2025, generated −$11.0M in free cash flow, an increase of $3.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Werewolf Therapeutics filings at SEC.gov ↗